OMER – Omeros Corporation
Omeros CorporationOMER
$17.93Name : Omeros Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,297,922,560.00
EPSttm : 1.22
Omeros Corporation
$17.93
3.64%$0.63
OMER — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
16.5
Margin Of Safety %
Put/Call OI Ratio
0.55
EPS Next Q Diff
0.04
EPS Last/This Y
0.74
EPS This/Next Y
0.54
Price
17.3
Target Price
36.67
Analyst Recom
1.5
Performance Q
26.19
Upside
191.3%
Beta
3
Ticker: OMER
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | OMER | 19.65 | 0.59 | 0.34 | 60218 |
| 2026-10-13 | OMER | 18.89 | 0.59 | 0.90 | 61520 |
| 2026-10-14 | OMER | 18.41 | 0.60 | 0.15 | 62612 |
| 2026-10-15 | OMER | 18.79 | 0.60 | 0.39 | 62335 |
| 2026-10-16 | OMER | 16.19 | 0.58 | 0.67 | 65169 |
| 2026-10-19 | OMER | 16.35 | 0.60 | 0.35 | 57340 |
| 2026-10-20 | OMER | 16.54 | 0.60 | 0.94 | 58227 |
| 2026-10-21 | OMER | 16.24 | 0.60 | 0.34 | 58175 |
| 2026-10-22 | OMER | 16.87 | 0.60 | 0.32 | 58485 |
| 2026-10-23 | OMER | 16.55 | 0.59 | 0.64 | 59326 |
| 2026-10-26 | OMER | 16.31 | 0.59 | 0.25 | 59828 |
| 2026-10-27 | OMER | 17.49 | 0.59 | 0.02 | 59500 |
| 2026-10-28 | OMER | 17.88 | 0.57 | 1.53 | 60840 |
| 2026-10-29 | OMER | 18.86 | 0.57 | 0.32 | 61083 |
| 2026-10-30 | OMER | 18.46 | 0.56 | 0.53 | 61812 |
| 2026-11-02 | OMER | 17.82 | 0.55 | 0.21 | 62380 |
| 2026-11-03 | OMER | 18.29 | 0.56 | 2.50 | 62278 |
| 2026-11-04 | OMER | 18.2 | 0.56 | 0.05 | 62295 |
| 2026-11-05 | OMER | 17.15 | 0.56 | 0.21 | 62411 |
| 2026-11-06 | OMER | 16.92 | 0.56 | 0.14 | 62801 |
| 2026-11-09 | OMER | 17.47 | 0.55 | 0.21 | 63329 |
| 2026-11-10 | OMER | 17.28 | 0.55 | 0.12 | 63637 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | OMER | 19.64 | 93.8 | - | 0.69 |
| 2026-10-13 | OMER | 18.89 | 93.8 | - | 0.69 |
| 2026-10-14 | OMER | 18.43 | 93.8 | - | 0.69 |
| 2026-10-15 | OMER | 18.80 | 93.8 | - | 0.69 |
| 2026-10-16 | OMER | 16.17 | 93.8 | - | 0.69 |
| 2026-10-19 | OMER | 16.35 | 93.8 | - | 0.69 |
| 2026-10-20 | OMER | 16.35 | 93.8 | - | 0.69 |
| 2026-10-21 | OMER | 16.54 | 93.8 | - | 0.69 |
| 2026-10-22 | OMER | 16.87 | 93.8 | - | 0.69 |
| 2026-10-23 | OMER | 16.56 | 93.8 | - | 0.69 |
| 2026-10-26 | OMER | 16.30 | 93.8 | - | 0.69 |
| 2026-10-27 | OMER | 17.50 | 93.8 | - | 0.69 |
| 2026-10-28 | OMER | 17.89 | 93.8 | - | 0.69 |
| 2026-10-29 | OMER | 18.94 | 93.8 | - | 0.69 |
| 2026-10-30 | OMER | 18.45 | 93.8 | - | 0.69 |
| 2026-11-02 | OMER | 17.82 | 93.8 | - | 0.69 |
| 2026-11-03 | OMER | 18.27 | 93.8 | - | 0.69 |
| 2026-11-04 | OMER | 18.19 | 93.8 | - | 0.69 |
| 2026-11-05 | OMER | 17.06 | 93.8 | - | 0.69 |
| 2026-11-06 | OMER | 16.91 | 93.8 | - | 0.69 |
| 2026-11-09 | OMER | 17.57 | 93.8 | - | 0.69 |
| 2026-11-10 | OMER | 17.30 | 93.8 | - | 0.69 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | OMER | -3.82 | 8.69 | 16.43 |
| 2026-10-13 | OMER | -3.82 | 8.69 | 16.43 |
| 2026-10-14 | OMER | -3.82 | 8.69 | 16.43 |
| 2026-10-15 | OMER | -3.82 | 8.69 | 16.43 |
| 2026-10-16 | OMER | -3.82 | 8.69 | 16.43 |
| 2026-10-19 | OMER | -3.82 | 8.75 | 16.43 |
| 2026-10-20 | OMER | -3.82 | 8.75 | 16.43 |
| 2026-10-21 | OMER | -3.82 | 8.75 | 16.43 |
| 2026-10-22 | OMER | -3.82 | 8.75 | 16.43 |
| 2026-10-23 | OMER | -3.82 | 8.75 | 16.43 |
| 2026-10-26 | OMER | -3.82 | 8.59 | 16.43 |
| 2026-10-27 | OMER | -3.82 | 8.59 | 16.50 |
| 2026-10-28 | OMER | -3.82 | 8.59 | 16.50 |
| 2026-10-29 | OMER | -3.82 | 8.59 | 16.50 |
| 2026-10-30 | OMER | -3.82 | 8.59 | 16.50 |
| 2026-11-02 | OMER | -3.82 | 8.54 | 16.50 |
| 2026-11-03 | OMER | -3.82 | 8.54 | 16.50 |
| 2026-11-05 | OMER | -3.82 | 8.54 | 16.50 |
| 2026-11-06 | OMER | -3.82 | 8.54 | 16.50 |
| 2026-11-09 | OMER | -3.82 | 8.50 | 16.50 |
| 2026-11-10 | OMER | -3.82 | 8.50 | 16.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.02
Avg. EPS Est. Current Quarter
-0.02
Avg. EPS Est. Next Quarter
0.07
Insider Transactions
-3.82
Institutional Transactions
8.5
Beta
3
Average Sales Estimate Current Quarter
37
Average Sales Estimate Next Quarter
51
Fair Value
Quality Score
29
Growth Score
22
Sentiment Score
93
Actual DrawDown %
18.5
Max Drawdown 5-Year %
-87
Target Price
36.67
P/E
12.03
Forward P/E
16.36
PEG
P/S
32.6
P/B
P/Free Cash Flow
EPS
1.44
Average EPS Est. Cur. Y
0.69
EPS Next Y. (Est.)
1.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
324.88
Relative Volume
0.42
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
◆
OMER
Healthcare
$17.30
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.7
Range 1M
30.6%
Sup Dist
2.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
1750%
EPS NY
28.2%
52W%
73%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+138.3% upside
Upside
+138.3%
Quality
29
OMER — P/E HistoricalBiotechnology
Omeros CorporationSector: Healthcare
Industry: Biotechnology
Employees: 175
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER
Latest News
—
Caricamento notizie per OMER…
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading